|
[1]
|
Antimicrobial resistance: use of phage therapy in the management of resistant infections
Molecular Biology Reports,
2024
DOI:10.1007/s11033-024-09870-2
|
|
|
|
|
[2]
|
Surgical Antibiotic Prophylaxis in an Era of Antibiotic Resistance: Common Resistant Bacteria and Wider Considerations for Practice
Infection and Drug Resistance,
2021
DOI:10.2147/IDR.S319780
|
|
|
|
|
[3]
|
Insights Into Drug Resistance in Staphylococcus aureus
Infectious Diseases,
2021
DOI:10.5772/intechopen.98313
|
|
|
|
|
[4]
|
Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures
Palgrave Communications,
2020
DOI:10.1057/s41599-020-0478-4
|
|
|
|
|
[5]
|
Clinical utilization of bacteriophages: a new perspective to combat the antimicrobial resistance in Brazil
The Brazilian Journal of Infectious Diseases,
2020
DOI:10.1016/j.bjid.2020.04.010
|
|
|
|
|
[6]
|
Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures
Palgrave Communications,
2020
DOI:10.1057/s41599-020-0478-4
|
|
|
|
|
[7]
|
Community-acquired pneumonia: aetiology, antibiotic resistance and prospects of phage therapy
Journal of Chemotherapy,
2020
DOI:10.1080/1120009X.2020.1807231
|
|
|
|
|
[8]
|
Bacteriophage Procurement for Therapeutic Purposes
Frontiers in Microbiology,
2016
DOI:10.3389/fmicb.2016.01177
|
|
|
|
|
[9]
|
Bacteriophage-derived CHAP domain protein, P128, kills Staphylococcus cells by cleaving interpeptide cross-bridge of peptidoglycan
Microbiology
,
2014
DOI:10.1099/mic.0.079111-0
|
|
|
|